Carpmaels & Ransford is delighted to announce that it will welcome two new members to the partnership on the 1st July, Harvey Adams and Matthew Georgiou. The firm offers its clients top-tier expertise across all technology sectors and the addition of these two new partners will further strengthen its enviable reputation for European IP in the Life Sciences and Chemistry sectors.

Harvey joins the partnership from Mathys & Squire LLP bringing decades of experience and a stellar reputation for client service. He is recognised as one of the leading attorneys and advocates in contentious proceedings before the European Patent Office (EPO) and has been entrusted with the defence of many important patents for landmark drugs. His practice focuses on Biotechnology and Pharmaceuticals and he has a wealth of expertise including in-depth knowledge of regulatory data protection, orphan drug designations, clinical trial exemptions and patent term extensions. Harvey also practises in the fields of nutritional compositions, cosmetics, cosmeceuticals and diagnostics.

Matthew joined the firm in 2009 following qualification. His practice focuses on the Pharmaceutical and Chemistry sectors and he has likewise successfully supported some of the world’s largest companies in these sectors. He has particular experience of handling complex multi-party opposition proceedings and also advises on patent term extension strategies and regulatory exclusivity relating to medicinal products in Europe.

Speaking about the changes at the firm Richard Jackson, Managing Partner, said: “We are excited to welcome Harvey and Matthew into the partnership. Harvey comes to us with a truly exceptional reputation in the Life Sciences and Chemistry fields. Matthew has developed an impressive practice here at Carpmaels & Ransford in the same fields, including appearing at the CJEU in Luxembourg just last week. These latest additions to the partnership provide us with a great opportunity to expand further the globally recognised expertise of the firm.”